Ironwood Pharmaceuticals News

Ironwood Pharmaceuticals (NASDAQ:IRWD): Analysts Stay Bullish Despite Recent Stock Plunge

TipRanksMar 16 12:36 ET

Ironwood Pharmaceuticals Analyst Ratings

BenzingaMar 1 12:59 ET

Ironwood Pharmaceuticals: Strong Buy Rating on LINZESS Performance and Apraglutide Market Potential

TipRanksFeb 29 15:16 ET

Ironwood Pharmaceuticals Analyst Ratings

BenzingaFeb 16 10:56 ET

Ironwood Pharmaceuticals Receives 'Buy' Rating From Analyst Amid Strong Performance and Promising Drug Pipeline

TipRanksFeb 15 14:06 ET

Ironwood Pharmaceuticals Analyst Ratings

BenzingaJan 17 10:05 ET

Wells Fargo Initiates Coverage On Ironwood Pharmaceuticals With Overweight Rating, Announces Price Target of $20

BenzingaDec 14, 2023 07:39 ET

Ironwood Pharmaceuticals Analyst Ratings

BenzingaDec 14, 2023 07:34 ET

Ironwood Pharmaceuticals' Apraglutide Shows Promising Results in STARS Nutrition and VectivBio Trials: An Emphasis on Jason Butler's Buy Rating

TipRanksOct 16, 2023 14:55 ET

JMP Securities Initiates Coverage On Ironwood Pharmaceuticals With Market Outperform Rating, Announces Price Target of $22

BenzingaSep 28, 2023 05:55 ET

Ironwood Pharmaceuticals Analyst Ratings

BenzingaSep 28, 2023 05:54 ET

Piper Sandler Adjusts Price Target on Ironwood Pharmaceuticals to $19 From $16, Maintains Overweight Rating

MT NewswiresMay 23, 2023 09:17 ET

Capital One Securities Initiates IRWD at Overweight With $15 Price Target

MT NewswiresSep 2, 2022 09:36 ET

Ironwood Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo

Dow JonesAug 16, 2022 07:50 ET

Ironwood Pharmaceuticals Price Target Raised to $13.00/Share From $12.00 by Wells Fargo

Dow JonesAug 16, 2022 07:50 ET

Wells Fargo Maintains Equal-Weight on Ironwood Pharmaceuticals, Raises Price Target to $13

Benzinga Real-time NewsAug 16, 2022 07:44 ET

Ironwood Pharmaceuticals Analyst Ratings

Benzinga Analyst RatingsAug 16, 2022 07:40 ET